Cytokinetics Inc (NASDAQ: CYTK) is 6.16% higher on its value in year-to-date trading and has touched a low of $44.49 and a high of $84.05 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CYTK stock was last observed hovering at around $50.75 in the last trading session, with the day’s loss setting it -0.81%.
Currently trading at $49.94, the stock is 4.83% and 1.23% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.3 million and changing -1.60% at the moment leaves the stock -8.79% off its SMA200. CYTK registered -38.93% loss for a year compared to 6-month loss of -14.63%. The firm has a 50-day simple moving average (SMA 50) of $49.5078 and a 200-day simple moving average (SMA200) of $54.87775.
The stock witnessed a 2.02% gain in the last 1 month and extending the period to 3 months gives it a -5.84%, and is 9.18% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.34% over the week and 3.91% over the month.
Cytokinetics Inc (CYTK) has around 423 employees, a market worth around $5.89B and $3.22M in sales. Profit margin for the company is -17906.24%. Distance from 52-week low is 12.25% and -40.58% from its 52-week high. The company has generated returns on investments over the last 12 months (-77.33%).
with sales reaching $12.14M over the same period.The EPS is expected to grow by 3.86% this year, but quarterly earnings will post 103.25% year-over-year. Quarterly sales are estimated to grow 625.95% in year-over-year returns.
Cytokinetics Inc (CYTK) Top Institutional Holders
481.0 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 119.87% of the company’s shares. The shares outstanding are 117.89M, and float is at 113.56M with Short Float at 12.07%. Institutions hold 119.23% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 14.3958% of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $624.32 million to account for 11.3056 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 11.2218% and valued at over $619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.985 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Malik Fady Ibraham, the company’s EVP Research & Development. SEC filings show that Malik Fady Ibraham sold 2,000 shares of the company’s common stock on Jan 21 ’25 at a price of $45.92 per share for a total of $91840.0. Following the sale, the insider now owns 0.12 million shares.
Cytokinetics Inc disclosed in a document filed with the SEC on Jan 07 ’25 that Malik Fady Ibraham (EVP Research & Development) sold a total of 2,000 shares of the company’s common stock. The trade occurred on Jan 07 ’25 and was made at $49.32 per share for $98640.0. Following the transaction, the insider now directly holds 0.12 million shares of the CYTK stock.
Still, SEC filings show that on Jan 07 ’25, FADY MALIK (Officer) Proposed Sale 12,000 shares at an average price of $49.19 for $0.59 million. The insider now directly holds shares of Cytokinetics Inc (CYTK).
